Skip to content

Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

Raul G. Nogueira, Ashutosh Prabhakar Jadhav, Diogo C Haussen, Alain Bonafé, Ronald F. Budzik, Parita Bhuva, Dileep R. Yavagal, Marc Ribó, Christophe Cognard, Ricardó A. Hanel, Cathy A. Sila, Ameer E Hassan, Mónica Millán, Elad I. Levy, Peter John Mitchell, Michael Chen, Joey English, Qaisar A. Shah, Frank L. Silver, Vítor Mendes Pereira, Brijesh Mehta, Blaise Baxter, Michael G. Abraham, Pedro Cardona, Erol Veznedaroglu, Frank R Hellinger, Lei Feng, Jawad F. Kirmani, Demetrius Klee Lopes, Brian Thomas Jankowitz, Michael Frankel, Vincent Costalat, Nirav A. Vora, Albert J. Yoo, Amer M. Malik, Anthony J. Furlan, Marta Rubiera, Amin Aghaebrahim, Jean‐Marc Olivot, Wondwossen G. Tekle, Ryan D Shields, Todd Graves, Roger J. Lewis, Wade S. Smith, David S. Liebeskind, Jeffrey L. Saver, Tudor G. Jovin

New England Journal of Medicine · 2017 · 5,820 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafé, A., Budzik, R. F., Bhuva, P., Yavagal, D. R., Ribó, M., Cognard, C., Hanel, R. A., Sila, C. A., Hassan, A. E., Millán, M., Levy, E. I., Mitchell, P. J., Chen, M., English, J., Shah, Q. A., Silver, F. L., … Jovin, T. G. (2017). Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. New England Journal of Medicine, 378(1), 11–21. https://doi.org/10.1056/nejmoa1706442

In text: (Nogueira et al., 2017)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: The effect of endovascular thrombectomy that is performed more than 6 hours after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is disproportionately severe relative to the infarct volume may benefit from late thrombectomy. METHODS: We enrolled patients with occlusion of the intracranial internal carotid artery or proximal middle cerebral artery who had last been known to be well 6 to 24 hours earlier and who had a mismatch between the severity of the clinical deficit and the infarct volume, with mismatch criteria defined according to age (<80 years or ≥80 years). Patients were randomly assigned to thrombectomy plus standard care (the thrombectomy group) or to standard care alone (the control group). The coprimary end points were the mean score for disability on the utility-weighted modified Rankin scale (which ranges from 0 [death] to 10 [no symptoms or disability]) and the rate of functional independence (a score of 0, 1, or 2 on the modified Rankin scale, which ranges from 0 to 6, with higher scores indicating more severe disability) at 90 days. RESULTS: A total of 206 patients were enrolled; 107 were assigned to the thrombectomy group and 99 to the control group. At 31 months, enrollment in the trial was stopped because of the results of a prespecified interim analysis. The mean score on the utility-weighted modified Rankin scale at 90 days was 5.5 in the thrombectomy group as compared with 3.4 in the control group (adjusted difference [Bayesian analysis], 2.0 points; 95% credible interval, 1.1 to 3.0; posterior probability of superiority, >0.999), and the rate of functional independence at 90 days was 49% in the thrombectomy group as compared with 13% in the control group (adjusted difference, 33 percentage points; 95% credible interval, 24 to 44; posterior probability of superiority, >0.999). The rate of symptomatic intracranial hemorrhage did not differ significantly between the two groups (6% in the thrombectomy group and 3% in the control group, P=0.50), nor did 90-day mortality (19% and 18%, respectively; P=1.00). CONCLUSIONS: Among patients with acute stroke who had last been known to be well 6 to 24 hours earlier and who had a mismatch between clinical deficit and infarct, outcomes for disability at 90 days were better with thrombectomy plus standard care than with standard care alone. (Funded by Stryker Neurovascular; DAWN ClinicalTrials.gov number, NCT02142283 .).

  1. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.1993
  2. Tissue Plasminogen Activator for Acute Ischemic Stroke1995
  3. Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis2014
  4. Dabigatran versus Warfarin in Patients with Atrial Fibrillation2009
  5. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)2020

Metadata from OpenAlex (CC0). Citations are generated from the published record.